evidence: CDC Yellow Book 2024 [...] Disease data source: World Health Organization. International Travel and Health. Geneva, Switzerland: 2015. [...] The Advisory Committee on Immunization Practices (ACIP) recommends routine administration of a quadrivalent meningococcal conjugate vaccine (MenACWY) for all people aged 11–18 years. Administer a single dose of vaccine to patients at age 11 or 12 years and a booster dose at age 16 years. Routine immunization with MenACWY is not recommended for other age groups in the United States, except for people at increased risk for meningococcal disease, including those with a persistent complement component deficiency (C3, C5-9, properdin, factor D, factor H); people taking a complement component inhibitor (e.g., eculizumab [Soliris] or ravulizumab [Ultomiris]); people who have functional or anatomic asplenia; or people with HIV. ACIP describes vaccine, product, number of doses, and booster dose recommendations, based on age and risk factors for each risk group, in Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.